The Hong Kong Reality Check: Biotech Breakups, Reckless Shippers, and Boring MonopoliesGlobal Report·9 hours ago02142+4.19%02866+1.09%
Strategic Reshuffling in Hong Kong's Healthcare Cluster Amid Global Supply Chain ShiftsGlobal Report·1 day ago, 04:20 AM03320-0.21%01833+0.90%
Is HBM Holdings (SEHK:2142) Undervalued As Its Sinopharm Biologic Drug Consortium Takes Shape?Simplywall·Jul 28 at 02:13 PM02142+4.19%01099-1.53%
HBM Holdings enters strategic biologics R&D collaboration with SinopharmPUBT·Jul 27 at 04:00 AM01099-1.53%02142+4.19%
HBM Holdings Flags Strong Interim Earnings on Pharma PartnershipsTip Ranks·Jul 23 at 07:07 PM02142+4.19%
Harbour BioMed Announces Positive Profit Alert for 2026 Interim Results, Marking Seventh Consecutive Profitable Half-Year as Platform-Based Advantages Drive Sustainable GrowthPR Newswire·Jul 23 at 07:02 PM02142+4.19%BMY+0.69%
20:55 ETNona Biosciences Enters Research Collaboration with the Medical University of Vienna to Advance Fully Human Antibody Development for Infectious Diseasesprnewswire·Jul 22 at 07:56 PM02142+4.19%
Harbour BioMed and Kelun-Biotech receive China IND approval for asthma therapyPharmaceutical Technology·Jul 16 at 03:59 AM06990+0.58%02142+4.19%
China NMPA clears Kelun-Biotech, Harbour BioMed asthma IND for SKB575/HBM7575PUBT·Jul 15 at 05:02 AM06990+0.58%02142+4.19%
Harbour BioMed appoints Lloyd Klickstein scientific advisor for immunologyPUBT·Jun 28 at 08:28 PM02142+4.19%
